BioCentury
ARTICLE | Product Development

Progressing platforms

Why Mark McClellan is pushing for novel trial designs in rare diseases

March 17, 2018 12:58 AM UTC

Mark McClellan, director of the Duke-Margolis Center for Health Policy, is hopeful that attendees of the group’s March 19 meeting on novel statistical methods and trial designs will walk out with the tools they need to design and launch platform trials in rare diseases.

McClellan, who was previously FDA commissioner and administrator of CMS, joined Duke-Margolis in 2015 as its inaugural director to lead the center’s work on translational health policy research, analysis and implementation...